High hepatitis C incidence in relation to prescription opioid injection and poly-drug use: Assessing barriers to hepatitis C prevention

International Journal of Drug Policy

Volumn 47, Issue , 2017, Pages 61-68

  Puzhko, Svetlana ^a,b   Roy, Élise ^c,d   Jutras Aswad, Didier ^b,e   Artenie, Andreea Adelina ^b,e   Fortier, Emmanuel ^b,e   Zang, Geng ^b   Bruneau, Julie ^b,e  

^a MCGILL UNIVERSITY   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

^d INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

HCV incidence; Hepatitis C; Injection drug use; Prescription opioids; Prevention; Treatment

Indexed keywords

COCAINE; DIAMORPHINE; TRANQUILIZER; NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; INCIDENCE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE DRUG ABUSE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROCONVERSION; ADDICTION; CANADA; OPIATE ADDICTION; POLYPHARMACY; PSYCHOLOGY; RISK FACTOR; SUBSTANCE ABUSE; TRANSMISSION; YOUNG ADULT;

ADULT; ANALGESICS, OPIOID; BEHAVIOR, ADDICTIVE; CANADA; FEMALE; HEPATITIS C; HUMANS; INCIDENCE; MALE; OPIOID-RELATED DISORDERS; POLYPHARMACY; RISK FACTORS; SEROCONVERSION; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 85021712168     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2017.05.027     Document Type: Article

References (56)

1. Bandettini Di Poggio, A., Fornai, F., Paparelli, A., Pacini, M., Perugi, G., Maremmani, I., Comparison between heroin and heroin-cocaine polyabusers: A psychopathological study. Annals of the New York Academy of Sciences 1074 (2006), 438–445, 10.1196/annals.1369.044.
2. Brady, K.T., McCauley, J.L., Back, S.E., Prescription opioid misuse, abuse, and treatment in the United States: An update. American Journal of Psychiatry 173:1 (2016), 18–26, 10.1176/appi.ajp.2015.15020262.
3. Bruneau, J., Roy, E., Arruda, N., Zang, G., Jutras-Aswad, D., The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction 107:7 (2012), 1318–1327, 10.1111/j.1360-0443.2012.03803.x.
4. Darke, S., Self-report among injecting drug users: A review. Drug and Alcohol Dependence 51:3 (1998), 253–263 discussion 267–258.
5. Darke, S., Farrell, M., Which medications are suitable for agonist drug maintenance?. Addiction 111:5 (2016), 767–774, 10.1111/add.13158.
6. Darke, S., Kaye, S., Topp, L., Cocaine use in New South Wales, Australia, 1996–2000: 5 year monitoring of trends in price, purity, availability and use from the illicit drug reporting system. Drug and Alcohol Dependence 67:1 (2002), 81–88.
7. De, P., Cox, J., Boivin, J.F., Platt, R.W., Jolly, A.M., Rethinking approaches to risk reduction for injection drug users: Differences in drug type affect risk for HIV and hepatitis C virus infection through drug-injecting networks. Journal of Acquired Immune Deficiency Syndromes 46:3 (2007), 355–361, 10.1097/QAI.0b013e3181565dde.
8. Emmanuelli, J., Desenclos, J.C., Harm reduction interventions, behaviours and associated health outcomes in France, 1996–2003. Addiction 100:11 (2005), 1690–1700, 10.1111/j.1360-0443.2005.01271.x.
9. Firestone, M., Fischer, B., A qualitative exploration of prescription opioid injection among street-based drug users in Toronto: Behaviours, preferences and drug availability. Harm Reduction Journal, 5, 2008, 30, 10.1186/1477-7517-5-30.
10. Fischer, B., Argento, E., Prescription opioid related misuse, harms, diversion and interventions in Canada: A review. Pain Physician 15:Suppl. 3 (2012), Es191–Es203.
11. Fischer, B., Kirst, M., Rehm, J., Marsh, D., Bondy, S., Tyndall, M., The phenomenon of so-called ‘other drug use’ among opiate addicts in the North American context: Evidence, consequences, questions. Jellinek, C., Westermann, B., Bellmann, G.U., (eds.) Offene Grenzen der Substitution, 2000, BELTZ Deutscher Studien Verlag, Weinheim, Germany, 95–118.
12. Fischer, B., Kurdyak, P., Goldner, E., Tyndall, M., Rehm, J., Treatment of prescription opioid disorders in Canada: Looking at the ‘other epidemic’?. Substance Abuse Treatment, Prevention, and Policy, 11, 2016, 12, 10.1186/s13011-016-0055-4.
13. Florence, C.S., Zhou, C., Luo, F., Xu, L., The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Medical Care 54:10 (2016), 901–906, 10.1097/mlr.0000000000000625.
14. Folch, C., Merono, M., Casabona, J., Factors associated with sharing syringes among street-recruited injecting drug users. Medicina Clinica (Barcelona) 127:14 (2006), 526–532.
15. Gomes, T., Mamdani, M.M., Dhalla, I.A., Cornish, S., Paterson, J.M., Juurlink, D.N., The burden of premature opioid-related mortality. Addiction 109:9 (2014), 1482–1488, 10.1111/add.12598.
16. Gowing, L., Farrell, M., Bornemann, R., Ali, R., Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database of Systematic Reviews, 4, 2004, Cd004145, 10.1002/14651858.CD004145.pub2.
17. Hadland, S.E., DeBeck, K., Kerr, T., Feng, C., Montaner, J.S., Wood, E., Prescription opioid injection and risk of hepatitis C in relation to traditional drugs of misuse in a prospective cohort of street youth. BMJ Open, 4(7), 2014, e005419, 10.1136/bmjopen-2014-005419.
18. Hagan, H., Thiede, H., Des Jarlais, D.C., Hepatitis C virus infection among injection drug users: Survival analysis of time to seroconversion. Epidemiology 15:5 (2004), 543–549.
19. Hagan, H., Thiede, H., Weiss, N.S., Hopkins, S.G., Duchin, J.S., Alexander, E.R., Sharing of drug preparation equipment as a risk factor for hepatitis C. American Journal of Public Health 91:1 (2001), 42–46.
20. Harrell, P.T., Mancha, B.E., Petras, H., Trenz, R.C., Latimer, W.W., Latent classes of heroin and cocaine users predict unique HIV/HCV risk factors. Drug and Alcohol Dependence 122:3 (2012), 220–227, 10.1016/j.drugalcdep.2011.10.001.
21. Havens, J.R., Lofwall, M.R., Frost, S.D., Oser, C.B., Leukefeld, C.G., Crosby, R.A., Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. American Journal of Public Health 103:1 (2013), e44–e52, 10.2105/ajph.2012.300874.
22. Havens, J.R., Walker, R., Leukefeld, C.G., Prevalence of opioid analgesic injection among rural nonmedical opioid analgesic users. Drug and Alcohol Dependence 87:1 (2007), 98–102, 10.1016/j.drugalcdep.2006.07.008.
23. Higgins, S.T., Budney, A.J., Bickel, W.K., Applying behavioral concepts and principles to the treatment of cocaine dependence. Drug and Alcohol Dependence 34:2 (1994), 87–97.
24. Horyniak, D., Agius, P.A., Degenhardt, L., Reddel, S., Higgs, P., Aitken, C., et al. Patterns of, and factors associated with, illicit pharmaceutical opioid analgesic use in a prospective cohort of people who inject drugs in Melbourne, Australia. Substance Use & Misuse 50:13 (2015), 1650–1659, 10.3109/10826084.2015.1027928.
25. Horyniak, D., Higgs, P., Jenkinson, R., Degenhardt, L., Stoove, M., Kerr, T., et al. Establishing the Melbourne Injecting Drug User Cohort Study (MIX): Rationale, methods, and baseline and twelve-month follow-up results. Harm Reduction Journal, 10, 2013, 11, 10.1186/1477-7517-10-11.
26. International Narcotics Control Board. (2012). Narcotic drugs technical report: Estimated world requirements for 2012. Retrieved 15th May 2015 from. https://www.incb.org/documents/Narcotic-Drugs/Technical-Publications/2012/NDR_2012_Part2_Comments_E.pdf.
27. Jones, J.D., Mogali, S., Comer, S.D., Polydrug abuse: A review of opioid and benzodiazepine combination use. Drug and Alcohol Dependence 125:1 (2012), 8–18.
28. Judd, A., Hutchinson, S., Wadd, S., Hickman, M., Taylor, A., Jones, S., et al. Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: Cross sectional analysis. Journal of Viral Hepatitis 12:6 (2005), 655–662, 10.1111/j.1365-2893.2005.00643.x.
29. Keen, L. 2nd, Khan, M., Clifford, L., Harrell, P.T., Latimer, W.W., Injection and non-injection drug use and infectious disease in Baltimore city: Differences by race. Addictive Behaviors 39:9 (2014), 1325–1328, 10.1016/j.addbeh.2014.04.020.
30. Lankenau, S.E., Teti, M., Silva, K., Bloom, J.J., Harocopos, A., Treese, M., Patterns of prescription drug misuse among young injection drug users. Journal of Urban Health 89:6 (2012), 1004–1016, 10.1007/s11524-012-9691-9.
31. Li, L., Assanangkornchai, S., Duo, L., McNeil, E., Li, J., Risk behaviors, prevalence of HIV and hepatitis C virus infection and population size of current injection drug users in a China–Myanmar border city: Results from a respondent-driven sampling survey in 2012. PLoS One, 9(9), 2014, e106899, 10.1371/journal.pone.0106899.
32. Li, R., Chambless, L., Test for additive interaction in proportional hazards models. Annals of Epidemiology 17:3 (2007), 227–236, 10.1016/j.annepidem.2006.10.009.
33. Luciani, F., Bretana, N.A., Teutsch, S., Amin, J., Topp, L., Dore, G.J., et al. A prospective study of hepatitis C incidence in Australian prisoners. Addiction 109:10 (2014), 1695–1706, 10.1111/add.12643.
34. Marshall, B.D., Green, T.C., Yedinak, J.L., Hadland, S.E., Harm reduction for young people who use prescription opioids extra-medically: Obstacles and opportunities. International Journal of Drug Policy 31 (2016), 25–31, 10.1016/j.drugpo.2016.01.022.
35. Martins, S.S., Sampson, L., Cerda, M., Galea, S., Worldwide prevalence and trends in unintentional drug overdose: A systematic review of the literature. American Journal of Public Health 105:11 (2015), e29–e49, 10.2105/ajph.2015.302843.
36. Miller, C.L., Johnston, C., Spittal, P.M., Li, K., Laliberte, N., Montaner, J.S., et al. Opportunities for prevention: Hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 36:3 (2002), 737–742, 10.1053/jhep.2002.35065.
37. Nielsen, S., Larance, B., Degenhardt, L., Gowing, L., Kehler, C., Lintzeris, N., Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database of Systematic Reviews, 5, 2016, Cd011117, 10.1002/14651858.CD011117.pub2.
38. Nurco, D.N., Bonito, A.J., Lerner, M., Balter, M.B., Studying addicts over time: Methodology and preliminary findings. American Journal of Drug and Alcohol Abuse 2:2 (1975), 183–196.
39. Poisnel, G., Dhilly, M., Le Boisselier, R., Barre, L., Debruyne, D., Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regulation. Journal of Pharmacological Sciences 110:1 (2009), 36–46.
40. Release, S., SAS/STAT 9.3. User's guide. 2011, SAS Institute Inc, Cary, NC.
41. Rourke, S.B., Sobota, M., Tucker, R., Bekele, T., Gibson, K., Greene, S., et al. Social determinants of health associated with hepatitis C co-infection among people living with HIV: Results from the Positive Spaces, Healthy Places study. Open Med 5:3 (2011), e120–e131.
42. Roux, P., Villes, V., Blanche, J., Bry, D., Spire, B., Feroni, I., et al. Buprenorphine in primary care: Risk factors for treatment injection and implications for clinical management. Drug and Alcohol Dependence 97:1–2 (2008), 105–113, 10.1016/j.drugalcdep.2008.03.025.
43. Roy, E., Alary, M., Morissette, C., Leclerc, P., Boudreau, J.F., Parent, R., et al. High hepatitis C virus prevalence and incidence among Canadian intravenous drug users. International Journal of STD & AIDS 18:1 (2007), 23–27, 10.1258/095646207779949880.
44. Roy, E., Arruda, N., Bourgois, P., The growing popularity of prescription opioid injection in downtown Montreal: New challenges for harm reduction. Substance Use & Misuse 46:9 (2011), 1142–1150, 10.3109/10826084.2011.552932.
45. Roy, E., Arruda, N., Vaillancourt, E., Boivin, J.F., Morissette, C., Leclerc, P., et al. Drug use patterns in the presence of crack in downtown Montreal. Drug and Alcohol Review 31:1 (2012), 72–80, 10.1111/j.1465-3362.2011.00299.x.
46. Roy, E., Boudreau, J.F., Boivin, J.F., Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience. Drug and Alcohol Dependence 102:1–3 (2009), 158–161, 10.1016/j.drugalcdep.2009.01.006.
47. Strike, C., Millson, M., Hopkins, S., Smith, C., What is low threshold methadone maintenance treatment?. International Journal of Drug Policy 24:6 (2013), e51–e56, 10.1016/j.drugpo.2013.05.005.
48. Studio, R. (2012). R Studio: Integrated development environment for R: Version 0.97.
49. Tien, L.T., Ma, T., Fan, L.W., Loh, H.H., Ho, I.K., Autoradiographic analysis of GABAA receptors in mu-opioid receptor knockout mice. Neurochemical Research 32:11 (2007), 1891–1897, 10.1007/s11064-007-9373-2.
50. Tsui, J.I., Evans, J.L., Lum, P.J., Hahn, J.A., Page, K., Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Internal Medicine 174:12 (2014), 1974–1981, 10.1001/jamainternmed.2014.5416.
51. Turner, K.M., Hutchinson, S., Vickerman, P., Hope, V., Craine, N., Palmateer, N., et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: Pooling of UK evidence. Addiction 106:11 (2011), 1978–1988, 10.1111/j.1360-0443.2011.03515.x.
52. VanderWeele, T.J., Causal interactions in the proportional hazards model. Epidemiology 22:5 (2011), 713–717, 10.1097/EDE.0b013e31821db503.
53. VanderWeele, T.J., Knol, M.J., A tutorial on interaction. Epidemiologic Methods 3:1 (2014), 33–72.
54. Vickerman, P., Martin, N., Turner, K., Hickman, M., Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction 107:11 (2012), 1984–1995.
55. White, B., Dore, G.J., Lloyd, A.R., Rawlinson, W.D., Maher, L., Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: The HITS-c study. Medical Journal of Australia 201:6 (2014), 326–329.
56. Zibbell, J.E., Hart-Malloy, R., Barry, J., Fan, L., Flanigan, C., Risk factors for HCV infection among young adults in rural new york who inject prescription opioid analgesics. American Journal of Public Health 104:11 (2014), 2226–2232, 10.2105/ajph.2014.302142.